Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TLR7 | Q9NYK1 | 10/20 | 0.39 |
| ▸ | TLR8 | Q9NR97 | 6/20 | 0.39 |
| ▸ | PROKR1 | Q8TCW9 | 3/20 | 0.38 |
| ▸ | NLRP3 | Q96P20 | 2/20 | 0.36 |
| ▸ | CACNA2D1 | P54289 | 3/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26619911 | 1.00 | TLR7 (0.39) | TLR7TLR8PROKR1NLRP3CACNA2D1 | |
| SCHEMBL29036543 | 0.88 | TLR7 (0.41) | TLR7TLR8PROKR1KDM4EALDH1A1 | |
| SCHEMBL26713456 | 0.88 | TLR7 (0.41) | TLR7TLR8PROKR1KDM4EALDH1A1 | |
| SCHEMBL30074855 | 0.88 | TLR7 (0.41) | TLR7TLR8PROKR1KDM4EALDH1A1 | |
| SCHEMBL26619945 | 0.86 | PROKR1 (0.38) | TLR7TLR8PROKR1KDM4EALDH1A1 | |
| SCHEMBL26619943 | 0.86 | PROKR1 (0.38) | TLR7TLR8PROKR1KDM4EALDH1A1 | |
| SCHEMBL26619957 | 0.84 | PREP (0.37) | PROKR1CACNA2D1KMT2A | |
| SCHEMBL26619954 | 0.84 | PREP (0.37) | PROKR1CACNA2D1KMT2A | |
| SCHEMBL26619946 | 0.83 | NLRP3 (0.38) | TLR7TLR8PROKR1NLRP3KDM4E | |
| SCHEMBL26619951 | 0.83 | NLRP3 (0.38) | TLR7TLR8PROKR1NLRP3KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230348458-A1 | NLRP3 MODULATORS | INNATE TUMOR IMMUNITY, INC. | 2023-11-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230348458-A1 | NLRP3 MODULATORS | NLRP3, NLRP1, PYCARD | TLR7 238/4885TLR8 215/4885PROKR1 2933/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.